Navigation Links
Pain Relief in Just One Visit with Genzyme's Synvisc-One
Date:3/23/2009

Single-injection products will drive the US Hyaluronic Acid Viscosupplementation market to nearly $1 billion by 2013, according to Millennium Research Group

WALTHAM, Mass., March 23 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Orthopedic Biomaterials 2009 report, the US launch of Genzyme Biosurgery's single-injection Synvisc-One will drive procedural growth in the hyaluronic acid (HA) viscosupplementation market. Released to the market in February 2009, Synvisc-One adoption will fuel HA viscosupplementation revenues to reach nearly $1 billion by 2013.

Prior to the launch, HA viscosupplementation treatments were available only in 3-and 5-injection regimens. Over the next several years, many physicians are expected to adopt single-injection products in place of the 3- and 5-injection treatments. Single-injection treatments, which offer greater convenience and less pain, will gain popularity among both patients and physicians over the next five years and will account for approximately one-third of treatments by 2013. With Synvisc-One currently the only approved single-injection treatment, Genzyme Biosurgery is positioned to benefit from this shift in preference.

"The HA viscosupplementation market is the fastest-growing segment of the orthopedic biomaterial market, fueled in particular by the rise of single-injection treatments," says Kevin Flewwelling, Manager of the Orthopedics division at MRG. "Now that Synvisc-One has approval in the US, the door is open for the release of other single-injection products that will be launched through to 2013, driving the high growth in this market."

In addition to HA viscosupplementation, MRG's US Markets for Orthopedic Biomaterials 2009 report covers bone graft substitutes, machined bone interbody devices, cell concentration systems, and knee cartilage repair. The report also provides coverage of all key industry competitors, including AlloSource, Biomet, Blackstone Medical (Orthofix), DePuy, Exactech, Ferring Pharmaceuticals, Genzyme Biosurgery, Integra LifeSciences, LifeNet Health, Medtronic Spinal and Biologics, Musculoskeletal Transplant Foundation, Orthovita, Osiris Therapeutics, Osteotech, RTI Biologics, sanofi-aventis, Smith & Nephew, Stryker, Synthes, Wright Medical Technology, and many more. Other reports in this series cover Europe and Asia Pacific.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
2. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
3. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
6. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
7. MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients
8. invivodata Captures Symptom Relief Data in Endometriosis Trial
9. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
10. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
11. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  Andre, DiMino, CEO ... developer and manufacturer of innovative technologies and products, commented ... reported on February 21, 2017 in the Company,s quarterly ... ADMT CEO Andre, DiMino stated "During the ... business plan by devoting a larger portion of our ...
(Date:2/22/2017)... HAYWARD, Calif., Feb. 22, 2017  Ultra Clean ... supplier of critical systems and subsystems for the ... research industries, today reported its financial results for ... 30, 2016. "2016 was a year ... semiconductor revenue reached record highs and together with ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... partnering deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605680-summary/view-report.html Description The Global Spinal Cord Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... worries, or problems. He has also continued to spiritually evolve, which is the purpose ... published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® ... of individuals who have recently fallen victim to America’s opioid epidemic. Now, opiate dependent ... California, where they are free from the shame, stigma, and harmful labeling ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as well ... solution helps transform the HCC Risk Adjustment process from a typical fragmented ...
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
Breaking Medicine News(10 mins):